Skip to main content

Advertisement

Table 1 Anthropometric and clinical variables according to type of non-oral estradiol (intranasal or percutaneous gel)

From: Effects of micronized progesterone added to non-oral estradiol on lipids and cardiovascular risk factors in early postmenopause: a clinical trial

  Baseline E2 E2+P P
  Intranasal Percutaneous Intranasal Percutaneous Intranasal Percutaneous  
  n = 40 n = 46 n = 40 n = 46 n = 40 n = 46  
BMI 26 ± 3 26 ± 3 26 ± 3 26 ± 3 26 ± 3 26 ± 3 0.6
Weight (kg) 66 ± 7 64 ± 9 66 ± 7 64 ± 9 66 ± 7 64 ± 10 0.6
WC (cm) 84 ± 6 84 ± 8 84 ± 6 84 ± 8 83.5 ± 5 83.6 ± 9 0.6
SBP (mmHg) 118 ± 15 119 ± 12 116 ± 15 114 ± 15 118 ± 14 116 ± 14 0.4
DBP (mmHg) 75 ± 7 77 ± 7 75 ± 9 74 ± 9 76 ± 10 74 ± 10 0.2
Total-c (mg/dL) 222 ± 31a† 211 ± 27a† 212 ± 31b† 201 ± 27b† 205 ± 31b† 200 ± 32b† 0.5
HDL-c (mg/dL) 63 ± 12 63 ± 18 62 ± 14 60 ± 15 63 ± 14 60 ± 16 0.2
LDL-c (mg/dL) 134 ± 28a† 125 ± 29a† 128 ± 32a,b† 118 ± 26a,b† 121 ± 26b† 117 ± 29b† 0.5
Triglycerides (mg/dL) 122 ± 49 117 ± 56 117 ± 48 114 ± 54 108 ± 42 115 ± 62 0.3
Fast glucose (mg/dL) 91 ± 11 92 ± 9 91 ± 8 91 ± 8 93 ± 11 91 ± 10 0.2
2h glucose (mg/dL) 106 ± 29 102 ± 23 113 ± 38 103 ± 35 110 ± 39 101 ± 31 0.2
Insulin (μU/mL) 7 (4–10) 6 (3–9) 6 (2–8) 7 (3–9) 6 (4–9) 7 (3–9) 0.2
Estradiol (pg/mL) 14 (8–17) 11 (5–20) 40 (9–121) 65 (20–119) 47 ( 13–68) 49 (10–96) 0.1
hsCRP (mg/L) 2.1 (0.4-3.9) 1.1 (0.3-2.3) 1.6 (0.5-3) 1.4 (0.2-3) 1.5 (0.5-2) 1 (0.2-2) 0.6
  1. Values expressed as median and interquartile range or mean ± SD. Two-way analysis of variance with repeated measures (non parametric variables were log-converted for statistical analysis and reconverted for presentation in table format). P = difference between intranasal and percutaneous treatment.
  2. † = P < 0.01 for difference between baseline, E2 and E2+P. Different superscript letters indicate statistical difference with Bonferroni multiple-comparison correction test (α < 5%).
  3. Baseline: before hormone therapy; E2: estradiol only; E2+P estradiol + micronized progesterone.
  4. Intranasal: 3 mg/day 17β estradiol by intranasal route (n = 40) for two months. Percutaneous: 1.5 mg/day 17β estradiol gel by percutaneous route (n = 53) for three months.
  5. BMI body mass index, DBP diastolic blood pressure, HDL-c high-density lipoprotein cholesterol, hsCRP high-sensitivity C-reactive protein test, LDL-c low-density lipoprotein cholesterol, SBP systolic blood pressure, Total-c total lipoprotein cholesterol, WC waist circumference, 2h glucose: glucose levels 2 hours after 75g oral glucose load.